These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

296 related items for PubMed ID: 23305331

  • 1. Hepatocellular carcinoma treated with sorafenib: early detection of treatment response and major adverse events by contrast-enhanced US.
    Sugimoto K, Moriyasu F, Saito K, Rognin N, Kamiyama N, Furuichi Y, Imai Y.
    Liver Int; 2013 Apr; 33(4):605-15. PubMed ID: 23305331
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Early response to anti-tumoral treatment in hepatocellular carcinoma--can quantitative contrast-enhanced ultrasound predict outcome?
    Knieling F, Waldner MJ, Goertz RS, Zopf S, Wildner D, Neurath MF, Bernatik T, Strobel D.
    Ultraschall Med; 2013 Feb; 34(1):38-46. PubMed ID: 23258770
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Change in arterial tumor perfusion is an early biomarker of lenvatinib efficacy in patients with unresectable hepatocellular carcinoma.
    Kuorda H, Abe T, Fujiwara Y, Okamoto T, Yonezawa M, Sato H, Endo K, Oikawa T, Sawara K, Takikawa Y.
    World J Gastroenterol; 2019 May 21; 25(19):2365-2372. PubMed ID: 31148907
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Impact of neo-adjuvant Sorafenib treatment on liver transplantation in HCC patients - a prospective, randomized, double-blind, phase III trial.
    Hoffmann K, Ganten T, Gotthardtp D, Radeleff B, Settmacher U, Kollmar O, Nadalin S, Karapanagiotou-Schenkel I, von Kalle C, Jäger D, Büchler MW, Schemmer P.
    BMC Cancer; 2015 May 11; 15():392. PubMed ID: 25957784
    [Abstract] [Full Text] [Related]

  • 15. Predictors of survival in patients with established cirrhosis and hepatocellular carcinoma treated with sorafenib.
    Inghilesi AL, Gallori D, Antonuzzo L, Forte P, Tomcikova D, Arena U, Colagrande S, Pradella S, Fani B, Gianni E, Boni L, Laffi G, Di Costanzo F, Marra F.
    World J Gastroenterol; 2014 Jan 21; 20(3):786-94. PubMed ID: 24574751
    [Abstract] [Full Text] [Related]

  • 16. Efficacy of Sorafenib for Advanced Hepatocellular Carcinoma and Prognostic Factors.
    Li J, Wang L, Cong N, Shi C, Bu W, Song J, Chen H.
    Hepatogastroenterology; 2014 Jun 21; 61(132):954-7. PubMed ID: 26158148
    [Abstract] [Full Text] [Related]

  • 17. The Impact of Combined Transarterial Chemoembolization on the Overall Survival of Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib.
    Chen L, Su H, Shao H, Xu K, Liang S, Liu J.
    Hepatogastroenterology; 2014 May 21; 61(131):802-8. PubMed ID: 26176077
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Outcomes of treatment with sorafenib in Egyptian patients with hepatocellular carcinoma: a retrospective cohort study.
    Nada Y, Rashad N, Eissa M, Ghonaim A, Farag K, Saadawi I, Sheha A, El Gewaity M, Abdel-Rahman O.
    Expert Rev Gastroenterol Hepatol; 2018 Jan 21; 12(1):99-107. PubMed ID: 29124987
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.